Corpura Fondkommission AB är finansiella rådgivare i samband med DanCann Pharma A/S noteringsemissionen

Nyheter från Corpura.

Fredagen den 2 oktober meddelande DanCann Pharma A/S (”DanCann Pharma” or “the Company”) att bolaget har fått godkännande för notering på Spotlight Stock Market och publicerar även prospekt inför noteringsemissionen. För mer information om DanCann Pharma och noteringsemissionen se nedan.

About DanCann Pharma, the upcoming issue of units and listing at Spotlight Stock Market
DanCann Pharma is a pharmaceutical biotechnology company that was established in March 2018 due to the poor access for cannabinoid-based drugs and pharmaceuticals shortly after the establishment of the new Pilot Programme with medical cannabis in Denmark. For that reason, DanCann Pharma today works with the mission of securing access to treatments with quality assured cannabinoid substances. DanCann Pharma make and handle prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused, at the moment, on pain patients with alternative needs and management to handle their illness.

DanCann Pharma is licensed for handling of euphoriant substances, and during the summer 2018, the Company was licensed as one of the first companies in Denmark to handle and cultivate cannabis for medical use. DanCann Pharma is a vertically integrated company with upcoming activities from cultivation to refining of cannabis- and cannabinoids. DanCann Pharma’s business plan has several tracks, including, but not limited to: imports, R&D, and own in-house production (cultivation, refining and formulation). DanCann Pharma’s first production site, BIOTECH PHARM1, where the cannabis bulk is to be prod ced, is under establishment, and is expected to be operational in start 2021. The Company has with the existing equity secured the construction and launch of BIOTECH PHARM1. During 2018, 2019 and 2020, DanCann Pharma has worked extensively on developing a comprehensive Quality Management System (QMS) to ensure that all regulations, approvals and quality requirements are in order prior to the construction of BIOTECH PHARM1. When operational, the production facility will be among the most advanced and efficient in the world of pharmaceutical cannabis cultivation.

DanCann Pharma’s second production site, BIOTECH PHARM2, where the cannabis bulk is to be transformed into various patient-friendly products is expected to be operational before the end of 2021. In connection with BIOTECH PHARM2 the company will also develop a Research and Development department that will build the foundation for future research into new cannabinoids as well as new ways to administer the cannabinoids. DanCann Pharma mainly focuses on solutions and developments around capsule and tablet-based pharmaceuticals – and the associated fast (instant) or slow dissolving.

As of today, over +100 distinct cannabinoids (potential APIs) has been identified in the cannabis plant. While the main focus has been on the two major compounds, THC and CBD, DanCann Pharma unlock the true potential of cannabis by providing patients with an exclusive product portfolio, including rare and novel cannabinoids. Novel cannabinoidbased
pharmaceuticals can unlock new treatment options and relief for a future wide range of diseases and conditions. By this the Company has a differentiated approach to the industry, by targeting supply and research of rare cannabinoids (APIs) for new, unexplored treatment options. DanCann Pharma aims to release the true potential of medical cannabis.

Beside their own production DanCann Pharma will import cannabinoid-based pharmaceuticals from third-party partnerships. The company signed a strategic supply agreement with MediPharm Labs for import of several new products that is expected to be available on the Danish market during Q1 2021. DanCann Pharma estimates sales and first turn-over of imported cannabis- and cannabinoid-based pharmaceuticals from third-party partnerships in
Q1-Q2 2021.

DanCann Pharma’s next step is in-house production lines where the active ingredients (APIs) will be formulated for pharmaceuticals in several different dosing technologies (both new and existing) with the result of various, patient- friendly products.

Summary of the offering
Subscription period: 7th to 23rd of October 2020.

Subscription price: DKK 22.50 per Unit. One (1) Unit consists of five (5) Shares of DKK 4.50 each and two (2) Warrants (series TO 1) free of payment.

Issue volume: The offer comprises of a maximum of 6 670 000 shares and a maximum of 2 668 000 warrants of series TO 1, corresponding to initially approximately DKK 30 million and at a later stage DKK 16 million, respectively. If the issue is fully subscribed and all associated warrants are exercised, DanCann will receive a capital injection totaling
approximately DKK 46 million before issuance costs.

Subscription commitments: The Company has received subscription commitments of approximately DKK 22.5 million, a total of approximately 75 per cent of the issue of Units.

Valuation (pre-money): Approximately DKK 63.3 million.

Number of shares before the issue of units: 14 060 800 Shares

Listing on Spotlight Stock Market: DanCann Pharma’s Shares and Warrants are planned to be listed on Spotlight Stock Market. The first day of trading is projected to be on 12 November 2020

Financial advisor
Corpura Fondkommission AB is the financial advisor of DanCann Pharma in connection with the issue of units.

For additional information regarding the issue of units, please contact:
Corpura Fondkommission AB

For more information regarding DanCann Pharma, please contact:
Jeppe Krog Rasmussen, CEO
Phone: +45 29 63 69 20

About DanCann Pharma A/S
DanCann Pharma A/S was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas.

Arkiv nyheter

Corpura agerade sole bookrunner i samband med LifeCleans riktade emission om cirka 32,3 MSEK

Läs mer »

Corpura agerar sole coordinator och joint bookrunner i samband med Dicot Pharmas företrädesemission om cirka 125 MSEK

Läs mer »

Corpura agerar finansiell rådgivare i samband med Adventure Box fullt garanterade företrädesemission om cirka 13,1 MSEK

Läs mer »

Corpura Fondkommission agerade finansiell rådgivare i samband med Acuvis övertecknade företrädesemission

Läs mer »

Corpura Fondkommission agerar finansiell rådgivare i samband med Acuvis fullt säkerställda företrädesemission samt föreslagna riktade emission av aktier om totalt cirka 50,1 MSEK

Läs mer »

Corpura Fondkommission agerar finansiell rådgivare i samband med ZignSecs företrädesemission av aktier om cirka 33,5 MSEK

Läs mer »

Corpura Fondkommission agerar finansiell rådgivare i samband med Biofrigas företrädesemission emission av units om lägst cirka 7,6 MSEK och högst cirka 24,7 MSEK

Läs mer »

Corpura Fondkommission agerar finansiell rådgivare i samband med Fluicells företrädesemission av units om cirka 30 MSEK

Läs mer »

Corpura Fondkommission agerade finansiell rådgivare i samband med NOSAs riktade emission av units om initialt cirka 20 MSEK

Läs mer »

Corpura Fondkommission agerar finansiell rådgivare i samband med Medimis företrädesemission av aktier om cirka 26,5 MSEK

Läs mer »